TY  - JOUR
AU  - Schmitz, Matthias
AU  - Canaslan, Sezgi
AU  - Espinosa, Juan Carlos
AU  - Fernández-Borges, Natalia
AU  - Villar-Piqué, Anna
AU  - Llorens, Franc
AU  - Varges, Daniela
AU  - Maass, Fabian
AU  - Torres, Juan Maria
AU  - Hermann, Peter
AU  - Zerr, Inga
TI  - Validation of Plasma and CSF Neurofilament Light Chain as an Early Marker for Sporadic Creutzfeldt-Jakob Disease.
JO  - Molecular neurobiology
VL  - 59
IS  - 9
SN  - 0893-7648
CY  - Totowa, NJ
PB  - Humana Press
M1  - DZNE-2022-01300
SP  - 1-9
PY  - 2022
AB  - Biomarkers are becoming increasingly important for the differential diagnosis of neurodegenerative diseases. Previous observations indicated neurofilament light chain (NfL) as a potential blood-based biomarker for sporadic Creutzfeldt-Jakob disease (sCJD). Here, we investigated the stability, inter-assay/intra-assay variation and the regulation of NfL levels in CSF and plasma in a large cohort of sCJD patients by using a single-molecule array (SIMOA). We defined cutoffs for an accurate diagnosis and measured plasma NfL level in prion-infected mice models at different time points to identify the potential dynamics throughout the disease. Our analyses confirmed CSF and plasma NfL as stable and consistent marker for sCJD. Receiver operating characteristic (ROC) curve analysis showed an AUC of 0.92-0.93 to distinguish sCJD from control groups. Newly defined cutoffs revealed good diagnostic accuracies of CSF and plasma NfL, indicated by a sensitivity of 80-83.5
KW  - Animals
KW  - Biomarkers
KW  - Creutzfeldt-Jakob Syndrome: diagnosis
KW  - Humans
KW  - Intermediate Filaments
KW  - Mice
KW  - Neurofilament Proteins
KW  - Prions
KW  - tau Proteins
KW  - Biomarkers (Other)
KW  - Diagnostic (Other)
KW  - Neurofilament light chain (Other)
KW  - Plasma (Other)
KW  - Sporadic Creutzfeldt-Jakob disease (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:35716271
DO  - DOI:10.1007/s12035-022-02891-7
UR  - https://pub.dzne.de/record/164856
ER  -